133 CRISPR/Cas9 gene-edited allogeneic CAR-T cells targeting CD33 show high preclinical efficacy against AML without long-term hematopoietic toxicity

• Jonathan Terrett,
• Brigid Mcewan,
• Daniel Hostetter,
• Luis Gamboa,
• Meghna Kuppuraju,
• Mohammed Ghonime,
• Robert Chain,
• Zinkal Padalia,
• Demetrios Kalaitzidis

Affiliations

Jonathan Terrett

1Crispr Therapeutics, Cambridge, MA, USA

Brigid Mcewan

2CrisprTx, Cambridge, MA, USA

Daniel Hostetter

2CrisprTx, Cambridge, MA, USA

Luis Gamboa

2CrisprTx, Cambridge, MA, USA

Meghna Kuppuraju

2CrisprTx, Cambridge, MA, USA

Mohammed Ghonime

2CrisprTx, Cambridge, MA, USA

Robert Chain

2CrisprTx, Cambridge, MA, USA

Zinkal Padalia

2CrisprTx, Cambridge, MA, USA

Demetrios Kalaitzidis

2CrisprTx, Cambridge, MA, USA